L1CAM and neoplasm: 7/42 (16.7%) of tumours with POLE, 26/127 (20.5 %) of tumours with MMR-D, 19/228 (8.3%) of tumours with p53 wt/NSMP and 45/55 (81.8%) of tumours with p53 abn were L1CAM positive (Table 1; Fig. 1a, b).